All entries for: Lyell Immunopharma, Inc.

January 26, 2026

Lyell Immunopharma, Inc.

Orphan Drug Designation

South San Francisco, California
201-500 employees

treatment of diffuse large B-cell lymphoma (DLBCL)/high grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements

Disease Area: Rare Disease
August 12, 2025

Lyell Immunopharma, Inc.

Neutral Outlook

South San Francisco, California
201-500 employees

Further, the Inflation Reduction Act of 2022 (the IRA), signed into law on August 16, 2022, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in the ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program.

Disease Area: Oncology
Drug Type: Biologic, Small Molecule
Scroll to Top